Molecular bases of the main CYP2D6 gene genetic polymorphisms, ethnic differences and pharmacological consequences
The CYP2D6 gene metabolizes approximately 25 % of drugs of clinical use and exhibits a marked genetic variation, thus according to the allelic variants carried by each individual three types of metabolism can be observed: poor (PM), extensive (EM) or ultrarapid (UM). There is also interethnic variat...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2007 |
| País: | Perú |
| Recursos: | Universidad Nacional Mayor de San Marcos |
| Repositorio: | Revistas - Universidad Nacional Mayor de San Marcos |
| Idioma: | español |
| OAI Identifier: | oai:revistasinvestigacion.unmsm.edu.pe:article/4968 |
| Acesso em linha: | https://revistasinvestigacion.unmsm.edu.pe/index.php/farma/article/view/4968 |
| Access Level: | acceso abierto |
| Palavra-chave: | Genetic polymorphism CYP2D6 pharmacogenetics genotyping Polimorfismo genético farmacogenética genotipificación |
| Resumo: | The CYP2D6 gene metabolizes approximately 25 % of drugs of clinical use and exhibits a marked genetic variation, thus according to the allelic variants carried by each individual three types of metabolism can be observed: poor (PM), extensive (EM) or ultrarapid (UM). There is also interethnic variation in the frequencies of PM, EM and UM individuals. Knowledge of the individual CYP2D6 metabolic status may be clinically and economically important and could provide the basis for a rational approach to drug prescription. |
|---|